| Genetic basis for clinical response to CTLA-4 blockade in melanoma A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ... New England Journal of Medicine 371 (23), 2189-2199, 2014 | 4639 | 2014 |
| Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ... Cell 165 (1), 35-44, 2016 | 3188 | 2016 |
| Mutations associated with acquired resistance to PD-1 blockade in melanoma JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ... New England Journal of Medicine 375 (9), 819-829, 2016 | 3108 | 2016 |
| Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ... Cell reports 19 (6), 1189-1201, 2017 | 1756 | 2017 |
| Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ... Cancer discovery 7 (2), 188-201, 2017 | 1215 | 2017 |
| Genetic mechanisms of immune evasion in colorectal cancer CS Grasso, M Giannakis, DK Wells, T Hamada, XJ Mu, M Quist, JA Nowak, ... Cancer discovery 8 (6), 730-749, 2018 | 453 | 2018 |
| PD-1 blockade expands intratumoral memory T cells A Ribas, DS Shin, J Zaretsky, J Frederiksen, A Cornish, E Avramis, E Seja, ... Cancer immunology research 4 (3), 194-203, 2016 | 417 | 2016 |
| Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ... Cell 183 (3), 818-834. e13, 2020 | 407 | 2020 |
| High response rate to PD-1 blockade in desmoplastic melanomas Z Eroglu, JM Zaretsky, S Hu-Lieskovan, DW Kim, A Algazi, DB Johnson, ... Nature 553 (7688), 347-350, 2018 | 325 | 2018 |
| Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017; 7: 188–201. doi: 10.1158/2159-8290 DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ... CD-16-1223.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 250 | |
| Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells B Homet Moreno, JM Zaretsky, A Garcia-Diaz, J Tsoi, G Parisi, L Robert, ... Cancer immunology research 4 (10), 845-857, 2016 | 160 | 2016 |
| T cell antigen discovery via trogocytosis G Li, MT Bethune, S Wong, AV Joglekar, MT Leonard, JK Wang, JT Kim, ... Nature methods 16 (2), 183-190, 2019 | 150 | 2019 |
| T cell antigen discovery via signaling and antigen-presenting bifunctional receptors AV Joglekar, MT Leonard, JD Jeppson, M Swift, G Li, S Wong, S Peng, ... Nature methods 16 (2), 191-198, 2019 | 149 | 2019 |
| PAK4 inhibition improves PD-1 blockade immunotherapy G Abril-Rodriguez, DY Torrejon, W Liu, JM Zaretsky, TS Nowicki, J Tsoi, ... Nature Cancer 1 (1), 46-58, 2020 | 123 | 2020 |
| Overcoming genetically based resistance mechanisms to PD-1 blockade DY Torrejon, G Abril-Rodriguez, AS Champhekar, J Tsoi, KM Campbell, ... Cancer discovery 10 (8), 1140-1157, 2020 | 121 | 2020 |
| Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma A Kalbasi, M Tariveranmoshabad, K Hakimi, S Kremer, KM Campbell, ... Science translational medicine 12 (565), eabb0152, 2020 | 102 | 2020 |
| Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 2018; 8: 730–749. doi: 10.1158/2159-8290 CS Grasso, M Giannakis, DK Wells, T Hamada, XJ Mu, M Quist, JA Nowak, ... CD-17-1327.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 85 | |
| Sensitive detection and analysis of neoantigen-specific T cell populations from tumors and blood S Peng, JM Zaretsky, AHC Ng, W Chour, MT Bethune, J Choi, A Hsu, ... Cell reports 28 (10), 2728-2738. e7, 2019 | 83 | 2019 |
| PD-1 blockade expands intratumoral memory T cells. Cancer Immunol. Res. 2016; 4: 194–203. doi: 10.1158/2326-6066 A Ribas, DS Shin, J Zaretsky, J Frederiksen, A Cornish, E Avramis, E Seja, ... CIR-15-0210.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 70 | |
| Tumor characteristics associated with benefit from pembrolizumab in advanced non–small cell lung cancer S Hu-Lieskovan, A Lisberg, JM Zaretsky, TR Grogan, H Rizvi, DK Wells, ... Clinical cancer research 25 (16), 5061-5068, 2019 | 69 | 2019 |
